<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT05086445</url>
  </required_header>
  <id_info>
    <org_study_id>17610</org_study_id>
    <secondary_id>J2A-JE-GZGB</secondary_id>
    <nct_id>NCT05086445</nct_id>
  </id_info>
  <brief_title>A Study of LY3502970 in Japanese Participants With Type 2 Diabetes Mellitus</brief_title>
  <official_title>A Single- and Multiple-Ascending Dose Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of LY3502970 in Japanese Participants With Type 2 Diabetes Mellitus</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Eli Lilly and Company</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Eli Lilly and Company</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      The main purpose of this study is to learn about the side effects of LY3502970 when given to&#xD;
      Japanese participants with type 2 diabetes mellitus (T2DM). Blood tests will be performed to&#xD;
      investigate how the body processes the study drug and how the study drug affects the body.&#xD;
      For each participant, the study will last up to 24 weeks, inclusive of screening and will&#xD;
      include 10 visits to the study center.&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Not yet recruiting</overall_status>
  <start_date type="Anticipated">November 12, 2021</start_date>
  <completion_date type="Anticipated">June 18, 2022</completion_date>
  <primary_completion_date type="Anticipated">June 18, 2022</primary_completion_date>
  <phase>Phase 1</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Basic Science</primary_purpose>
    <masking>Double (Participant, Investigator)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Number of Participants with One or More Treatment Emergent Adverse Events (TEAEs) and Serious Adverse Event(s) (SAEs) Considered by the Investigator to be Related to Study Drug Administration</measure>
    <time_frame>Baseline through Week 15</time_frame>
    <description>A summary of TEAEs, SAEs and other non-serious adverse events (AEs), regardless of causality, will be reported in the Reported Adverse Events module</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Pharmacokinetics (PK): Maximum Concentration (Cmax) of LY3502970</measure>
    <time_frame>Predose on Day 1 through up to Day 88</time_frame>
    <description>PK: Cmax of LY3502970</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>PK: Area Under the Concentration Versus Time Curve (AUC) of LY3502970</measure>
    <time_frame>Predose on Day 1 through up to Day 88</time_frame>
    <description>PK: AUC of LY3502970</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change from Baseline in Fasting Glucose</measure>
    <time_frame>Baseline through Day 85</time_frame>
    <description>Change from Baseline in Fasting Glucose</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change from Baseline in Glycated Hemoglobin (HbA1c)</measure>
    <time_frame>Baseline through Day 85</time_frame>
    <description>Change from Baseline in HbA1c</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change from Baseline in Body Weight</measure>
    <time_frame>Baseline through Day 88</time_frame>
    <description>Change from Baseline in Body Weight</description>
  </secondary_outcome>
  <number_of_arms>4</number_of_arms>
  <enrollment type="Anticipated">65</enrollment>
  <condition>Diabetes Mellitus, Type 2</condition>
  <arm_group>
    <arm_group_label>LY3502970 (Part A)</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Single doses of LY3502970 administered orally.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>LY3502970 (Part B)</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Multiple doses of LY3502970 administered orally.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Placebo (Part A)</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>Placebo administered orally.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Placebo (Part B)</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>Placebo administered orally.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>LY3502970</intervention_name>
    <description>Administered orally</description>
    <arm_group_label>LY3502970 (Part A)</arm_group_label>
    <arm_group_label>LY3502970 (Part B)</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Placebo</intervention_name>
    <description>Administered orally</description>
    <arm_group_label>Placebo (Part A)</arm_group_label>
    <arm_group_label>Placebo (Part B)</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Males and females not of childbearing potential&#xD;
&#xD;
          -  Have type 2 diabetes mellitus (T2DM) diagnosed for at least 1 year&#xD;
&#xD;
          -  Have glycated hemoglobin (HbA1c) value ≥ 7.0% and ≤ 10.0% for participants treated&#xD;
             with diet and exercise or HbA1c ≥ 6.5% and ≤ 9.0% for participants who have washed out&#xD;
             antidiabetic medications at screening&#xD;
&#xD;
          -  Have type 2 diabetes controlled with diet and exercise alone or are stable on a single&#xD;
             oral antidiabetic medication (OAM); either metformin, DPP-4 (dipeptidyl peptidase-4)&#xD;
             inhibitor, or SGLT2 (sodium-glucose co-transporter-2) inhibitor within 3 months prior&#xD;
             to screening. Participants must withdraw from their OAM treatment for at least 28 days&#xD;
             prior to dosing.&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Have type 1 diabetes mellitus or latent autoimmune diabetes in adults.&#xD;
&#xD;
          -  Have uncontrolled diabetes defined as an episode of ketoacidosis or hyperosmolar state&#xD;
             requiring hospitalization&#xD;
&#xD;
          -  Have had an episode of severe hypoglycemia, as defined by the occurrence of&#xD;
             neuroglycopenic symptoms requiring the assistance of another person for recovery or&#xD;
             have a history of hypoglycemia unawareness or poor recognition of hypoglycemic&#xD;
             symptoms.&#xD;
&#xD;
          -  Have a history of acute or chronic pancreatitis or fasting serum triglyceride level of&#xD;
             &gt;500 milligram per deciliter (mg/dL).&#xD;
&#xD;
          -  Have known liver disease, obvious clinical signs or symptoms of liver disease, acute&#xD;
             or chronic hepatitis, or have elevations in aminotransferases (alanine&#xD;
             aminotransferase [ALT] and aspartate aminotransferase [AST]) greater than 3× upper&#xD;
             limit of normal (ULN).&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>20 Years</minimum_age>
    <maximum_age>70 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Call 1-877-CTLILLY (1-877-285-4559) or 1-317-615-4559 Mon - Fri 9 AM - 5 PM Eastern time (UTC/GMT - 5 hours, EST)</last_name>
    <role>Study Director</role>
    <affiliation>Eli Lilly and Company</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>There may be multiple sites in this clinical trial. 1-877-CTLILLY (1-877-285-4559) or</last_name>
    <phone>1-317-615-4559</phone>
    <email>ClinicalTrials.gov@Lilly.com</email>
  </overall_contact>
  <location>
    <facility>
      <name>P-One Clinic</name>
      <address>
        <city>Hachioji</city>
        <state>Tokyo</state>
        <zip>192-0071</zip>
        <country>Japan</country>
      </address>
    </facility>
    <contact>
      <phone>81120023812</phone>
    </contact>
    <investigator>
      <last_name>Kenichi Furihata</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Clinical Research Hospital Tokyo</name>
      <address>
        <city>Shinjuku-ku</city>
        <state>Tokyo</state>
        <zip>162-0053</zip>
        <country>Japan</country>
      </address>
    </facility>
    <contact>
      <phone>81120023812</phone>
    </contact>
    <investigator>
      <last_name>Hiroyuki Fukase</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Medical Corporation Houeikai Sekino Clinical Pharmacology Clinic</name>
      <address>
        <city>Toshima</city>
        <state>Tokyo</state>
        <zip>171-0014</zip>
        <country>Japan</country>
      </address>
    </facility>
    <contact>
      <phone>81120023812</phone>
    </contact>
    <investigator>
      <last_name>Hisakuni Sekino</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Yokohama Minoru Clinic</name>
      <address>
        <city>Yokohama</city>
        <zip>232-0064</zip>
        <country>Japan</country>
      </address>
    </facility>
    <contact>
      <phone>81120023812</phone>
    </contact>
    <investigator>
      <last_name>Chino Nakamura</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>Japan</country>
  </location_countries>
  <verification_date>November 1, 2021</verification_date>
  <study_first_submitted>October 20, 2021</study_first_submitted>
  <study_first_submitted_qc>October 20, 2021</study_first_submitted_qc>
  <study_first_posted type="Actual">October 21, 2021</study_first_posted>
  <last_update_submitted>November 3, 2021</last_update_submitted>
  <last_update_submitted_qc>November 3, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">November 4, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Diabetes Mellitus</mesh_term>
    <mesh_term>Diabetes Mellitus, Type 2</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

